LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Deschisă

SectorSănătate

6.84 -2.43

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

6.72

Maxim

6.96

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.833 49.888
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-26.58% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-21M 362M
Deschiderea anterioară	9.27
Închiderea anterioară	6.84

Sentimentul știrilor

By Acuity

51%

49%

257 / 344 Clasament în Healthcare

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iun. 2026, 23:22 UTC

Câștiguri

Principalele dinamici ale pieței

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 iun. 2026, 23:09 UTC

Acțiuni populare

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 iun. 2026, 20:51 UTC

Câștiguri

Costco Reports 15% Sales Growth in May

3 iun. 2026, 20:43 UTC

Câștiguri

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 iun. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 iun. 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 iun. 2026, 23:15 UTC

Market Talk

Câștiguri

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 iun. 2026, 22:08 UTC

Acțiuni populare

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 iun. 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 iun. 2026, 21:18 UTC

Câștiguri

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 iun. 2026, 21:15 UTC

Câștiguri

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 iun. 2026, 21:12 UTC

Câștiguri

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 iun. 2026, 21:09 UTC

Câștiguri

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 iun. 2026, 21:03 UTC

Câștiguri

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 iun. 2026, 20:43 UTC

Câștiguri

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 iun. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 iun. 2026, 20:37 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 iun. 2026, 20:35 UTC

Câștiguri

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Adj EPS $2.44 >AVGO

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q EPS $1.91 >AVGO

3 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Rev $22.19B >AVGO

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-26.58% jos

Prognoză pe 12 luni

Medie 5 USD -26.58%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

257 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.